It was suspected all along. Proof is finally found in a recent Abbott (Ireland) patent.
Cardiac stents are bigger than any other indication because patients commonly use multiple stents per procedure. So this is easily the largest indication.
We are looking at double digit millions per quarter if not triple, easily, and Osiris has the patents that Abbott needs. We get millions, Abbott gets billions. If Abbott ignores, there is Boston Scientific and JNJ.
Stent wars has begun.
Let the games begin.
Hold what you have and accumulate until news formally breaks.